Work

Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM).

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.7541

Authors: Akshanth Polepally, Jesus D Badillo, Carla Biesdorf de Almeida, Peter M. Voorhees, Anita D'Souza, Shaji Kumar, Orlando Felix Bueno, Tanya Rosenberg, Rajvineeth Kumar Pothacamury, Chetasi Talati, Rajeev Menon, Sven Mensing, Benjamin Engelhardt

Institutions: AbbVie (United States), AbbVie (Germany), Levine Cancer Institute, Wake Forest University, Froedtert Hospital, Medical College of Wisconsin Cancer Center, Mayo Clinic

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399480710

Cites:

Cited by:

Related to: 10